FibroGen

IPO

Landing Page | Kyntra Bio

Public · San Francisco, United States · Founded 1993 · $261.5M raised

Employees
11–50
Founded
1993
Business Model
B2B
Total Funding
$261.5M
Last Round
$50.0M Venture RoundNov 2022
Rounds
7
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

FibroGen (now operating as Kyntra Bio) is a biopharmaceutical company developing first-in-class medicines for life-threatening conditions, with a pipeline focused on anemia associated with lower-risk myelodysplastic syndrome and metastatic castration-resistant prostate cancer. Its lead programs include roxadustat, an oral HIF-PHI approved in multiple regions for anemia in chronic kidney disease, and FG-3246, an antibody-drug conjugate targeting prostate cancer.

Summary

FibroGen is a Biotech company based in San Francisco, United States, founded in 1993. It has raised $261.5M in total across 7 rounds, most recently a $50.0M Venture Round in Nov 2022. Investors include American Express Financial.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Venture RoundRoyalty Monetization FinancingNov 2022
$50.0M

Sign up to see all 8 events

Funding: Series E through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

FibroGen on Indexed.vc
<a href="https://indexed.vc/companies/fibrogen"><img src="https://indexed.vc/api/badge/company/fibrogen" alt="FibroGen on Indexed.vc" width="260" height="76" /></a>